COVID-19 Vaccine Acceptance and Hesitancy Among Health Care Workers in Lebanon.


Journal

Journal of epidemiology and global health
ISSN: 2210-6014
Titre abrégé: J Epidemiol Glob Health
Pays: Switzerland
ID NLM: 101592084

Informations de publication

Date de publication:
03 2023
Historique:
received: 23 06 2022
accepted: 12 01 2023
pubmed: 4 2 2023
medline: 15 3 2023
entrez: 3 2 2023
Statut: ppublish

Résumé

Lebanon endured its worst economic and financial crisis in 2020-2021. To minimize the impact of COVID-19 pandemic, it is important to improve the overall COVID-19 vaccination rate. Given that vaccine hesitancy among health care workers (HCWs) affects the general population's decision to be vaccinated, our study assessed COVID-19 vaccine acceptance among Lebanon HCWs and identified barriers, demographic differences, and the most trusted sources of COVID-19 information. A cross-sectional study was conducted between January and May 2021 among HCWs across nine hospitals, the Orders of Physicians, Nurses, and Pharmacists in Lebanon. Descriptive statistics were performed to evaluate the COVID-19 vaccine acceptance, and univariate and multivariable to identify their predictors. Among 879 participants, 762 (86.8%) were willing to receive the COVID-19 vaccine, 52 (5.9%) refused, and 64 (7.3%) were undecided. Males (226/254; 88.9%) and those ≥ 55 years (95/100; 95%) had the highest rates of acceptance. Of the 113 who were not willing to receive the vaccine, 54.9% reported that the vaccine was not studied well enough. Participants with a previous SARS-CoV-2 infection and those who did not know if they had a previous infection (p = 0.002) were less likely to accept the vaccine compared to those with no previous infection. The most trusted COVID-19 sources of information were WHO (69.3%) and healthcare providers (68%). Lebanese HCWs had a relatively high acceptance rate for COVID-19 vaccination compared to other countries. Our findings are important in informing the Lebanese health care authorities to establish programs and interventions to improve vaccine uptake among HCWs and the general population.

Sections du résumé

BACKGROUND
Lebanon endured its worst economic and financial crisis in 2020-2021. To minimize the impact of COVID-19 pandemic, it is important to improve the overall COVID-19 vaccination rate. Given that vaccine hesitancy among health care workers (HCWs) affects the general population's decision to be vaccinated, our study assessed COVID-19 vaccine acceptance among Lebanon HCWs and identified barriers, demographic differences, and the most trusted sources of COVID-19 information.
METHODS
A cross-sectional study was conducted between January and May 2021 among HCWs across nine hospitals, the Orders of Physicians, Nurses, and Pharmacists in Lebanon. Descriptive statistics were performed to evaluate the COVID-19 vaccine acceptance, and univariate and multivariable to identify their predictors.
RESULTS
Among 879 participants, 762 (86.8%) were willing to receive the COVID-19 vaccine, 52 (5.9%) refused, and 64 (7.3%) were undecided. Males (226/254; 88.9%) and those ≥ 55 years (95/100; 95%) had the highest rates of acceptance. Of the 113 who were not willing to receive the vaccine, 54.9% reported that the vaccine was not studied well enough. Participants with a previous SARS-CoV-2 infection and those who did not know if they had a previous infection (p = 0.002) were less likely to accept the vaccine compared to those with no previous infection. The most trusted COVID-19 sources of information were WHO (69.3%) and healthcare providers (68%).
CONCLUSION
Lebanese HCWs had a relatively high acceptance rate for COVID-19 vaccination compared to other countries. Our findings are important in informing the Lebanese health care authorities to establish programs and interventions to improve vaccine uptake among HCWs and the general population.

Identifiants

pubmed: 36735184
doi: 10.1007/s44197-023-00086-4
pii: 10.1007/s44197-023-00086-4
pmc: PMC9896451
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-66

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Vaccine. 2016 Sep 22;34(41):5013-5020
pubmed: 27576074
IJID Reg. 2021 Dec;1:20-26
pubmed: 35721775
Vaccines (Basel). 2021 Feb 03;9(2):
pubmed: 33546165
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
Vaccines (Basel). 2021 Jun 25;9(7):
pubmed: 34202107
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Vaccine. 2020 Oct 21;38(45):7002-7006
pubmed: 32988688
PLoS One. 2021 Sep 3;16(9):e0257109
pubmed: 34478470
JAMA. 2020 Aug 11;324(6):548-549
pubmed: 32722763
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207018
Int J Infect Dis. 2021 Aug;109:286-293
pubmed: 34242765
Hum Vaccin Immunother. 2021 Sep 2;17(9):2946-2950
pubmed: 34018902
Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621
pubmed: 33242386
Int J Health Plann Manage. 2021 Jan;36(1):13-17
pubmed: 32857892
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Int J Environ Res Public Health. 2022 Jan 07;19(2):
pubmed: 35055476
Hum Vaccin Immunother. 2021 Oct 3;17(10):3384-3393
pubmed: 34309482
Soc Sci Med. 2021 Feb;270:113684
pubmed: 33485008
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
JMIR Med Inform. 2020 Sep 22;8(9):e20477
pubmed: 32903197
Front Oncol. 2021 Jun 10;11:685107
pubmed: 34195088
Front Public Health. 2021 Aug 13;9:698111
pubmed: 34485229
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478623
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
Am J Infect Control. 2021 Feb;49(2):137-142
pubmed: 33227323
Am J Infect Control. 2021 Sep;49(9):1152-1157
pubmed: 33930516
Vaccines (Basel). 2021 May 02;9(5):
pubmed: 34063313
BMC Public Health. 2021 May 27;21(1):998
pubmed: 34044790
J Eval Clin Pract. 2021 Oct;27(5):1112-1122
pubmed: 33960582
BMJ Open. 2020 May 12;10(5):e035225
pubmed: 32404392
BMC Prim Care. 2022 Apr 15;23(1):81
pubmed: 35421920
J Hosp Infect. 2021 Feb;108:168-173
pubmed: 33259883
Front Public Health. 2022 Mar 25;10:878159
pubmed: 35400032
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-9
pubmed: 34752716
Medicine (Baltimore). 2021 May 7;100(18):e25825
pubmed: 33950990
Psychol Med. 2022 Oct;52(14):3127-3141
pubmed: 33305716

Auteurs

Nour J Youssef (NJ)

Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra , 1107, Beirut, Lebanon.
Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra, 1107, Beirut, Lebanon.

Nadim K Tfaily (NK)

Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra , 1107, Beirut, Lebanon.

Mohammad Bahij M Moumneh (MBM)

Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra , 1107, Beirut, Lebanon.

Celina F Boutros (CF)

Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra , 1107, Beirut, Lebanon.

Jad A Elharake (JA)

Yale Institute for Global Health, New Haven, CT, 06510, USA.
Department of Internal Medicine, Infectious Disease, Yale School of Medicine, New Haven, CT, 06510, USA.

Amyn A Malik (AA)

Yale Institute for Global Health, New Haven, CT, 06510, USA.
Department of Internal Medicine, Infectious Disease, Yale School of Medicine, New Haven, CT, 06510, USA.

SarahAnn M McFadden (SM)

Yale Institute for Global Health, New Haven, CT, 06510, USA.
Department of Internal Medicine, Infectious Disease, Yale School of Medicine, New Haven, CT, 06510, USA.

Bayan Galal (B)

Yale University, New Haven, CT, 06520, USA.

Inci Yildirim (I)

Yale Institute for Global Health, New Haven, CT, 06510, USA.
Department of Internal Medicine, Infectious Disease, Yale School of Medicine, New Haven, CT, 06510, USA.

Kaveh Khoshnood (K)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06510, USA.

Saad B Omer (SB)

Yale Institute for Global Health, New Haven, CT, 06510, USA.
Department of Internal Medicine, Infectious Disease, Yale School of Medicine, New Haven, CT, 06510, USA.
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06510, USA.
Yale School of Nursing, Orange, CT, 06477, USA.

Ziad A Memish (ZA)

Research and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh, Kingdom of Saudi Arabia.
College of Medicine, Al Faisal University, Riyadh, Kingdom of Saudi Arabia.
Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Ghassan S Dbaibo (GS)

Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra , 1107, Beirut, Lebanon. gdbaibo@aub.edu.lb.
Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Hamra, 1107, Beirut, Lebanon. gdbaibo@aub.edu.lb.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH